TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
In a small single-arm study, 16 breast cancer survivors with cancer-related cognitive impairment reported improved cognitive function after eight weeks of oxaloacetate. Fatigue and physical functioning also improved, but without a control group the findings cannot show that the supplement caused the changes; a placebo-controlled phase II trial is planned.
A small study found that 16 breast cancer survivors with cancer-related cognitive impairment reported improved cognitive function after taking oxaloacetate for eight weeks, according to a report published October 23 in JCO Oncology Advances. The uncontrolled findings are preliminary, and researchers plan to test the supplement against a placebo in a phase II trial.
The study enrolled 18 patients who were one to five years past cancer treatment and had moderately severe cognitive impairment on a screening questionnaire. Participants took 500 milligrams of oxaloacetate twice daily for eight weeks. Two patients did not complete the study; the main outcome analysis included the 16 who did.
On the FACT-Cog PCI, a measure of patients’ perceived cognitive impairment, the group’s mean score rose from 29.1 at baseline to 55.5 after eight weeks. The study report said the increase moved the group average from an impaired range into the normal range. Improvements were observed by week four and generally increased during the remaining four weeks.
The researchers also reported gains in fatigue and physical functioning, along with a trend toward improved insomnia. Neuropsychological testing showed improvement in executive function and processing speed. Gastrointestinal symptoms—including indigestion, bloating, constipation and diarrhea—were among the reported side effects. The source report describes treatment as generally well tolerated aside from these symptoms.
A Possible New Approach to Brain Fog
Cancer-related cognitive impairment can affect memory, attention, processing speed and daily functioning after treatment. The study adds an early signal for a supplement-based approach to a problem for which drug options are limited. Its reported changes in fatigue and physical functioning may also matter to survivors coping with several post-treatment symptoms at once.
However, the results do not establish that oxaloacetate caused the improvement. Without a comparison group, researchers cannot separate a treatment effect from factors such as expectations, changes over time or other influences. A larger randomized, placebo-controlled study is needed to determine whether the supplement works, how consistently it helps and whether its benefits outweigh its risks.
As an affiliate, we earn on qualifying purchases.
Why Researchers Tested Oxaloacetate
Cancer-related cognitive impairment is often described as “chemo brain” or “brain fog,” though it can occur in people with different cancer types and treatments. Its causes are not fully understood. The report notes that some chemotherapy agents cross the blood-brain barrier and can have neurotoxic effects, but cognitive problems may have multiple contributing factors.
Oxaloacetate is a naturally occurring metabolite involved in cellular energy production and in regulation of glutamate, a neurotransmitter studied for its role in cognition. Prior research, including studies involving people with long COVID, provided a rationale for testing it. The investigators also cited the limited availability of pharmacological treatments for cancer-related cognitive impairment.
The trial initially used a two-step design, with a defined improvement threshold for the first nine participants. The report says preliminary results exceeded that threshold, leading investigators to revise the study design to finish with fewer participants and move more quickly toward a randomized trial. That change does not replace the need for controlled testing.
“These early findings give us a strong reason to continue studying oxaloacetate as a potential approach for managing cognitive problems after breast cancer treatment.”
— Patricia Ganz, MD, UCLA Health, quoted in a press release
FACT-Cog cognitive function assessment questionnaire
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
What the Early Results Cannot Show
The study was small and had no placebo or untreated comparison group, and two of the 18 enrolled patients did not complete it. The reported score gains therefore cannot establish that oxaloacetate itself produced the changes or predict how well the supplement would work in a broader group of patients.
The available report does not specify the exact frequency or severity of each gastrointestinal side effect, or provide enough information to establish longer-term safety. It also remains unclear whether benefits would persist after treatment ends, which patients might benefit most, and whether results would apply to people with other cancers or treatment histories.
brain fog journal for tracking memory and concentration
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
A Placebo-Controlled Trial Ahead
A phase II randomized, placebo-controlled study of oxaloacetate for cancer-related cognitive impairment is expected to begin enrollment before the end of 2026, according to the report. Comparing outcomes with a placebo group should help researchers assess whether changes in cognition and other symptoms are attributable to the supplement.
Further results will be needed to clarify the size and duration of any benefit, the supplement’s safety over a longer period and whether findings extend beyond breast cancer survivors. Until controlled evidence is available, the current study should be viewed as a reason for further investigation, not as confirmation that oxaloacetate treats cancer-related cognitive impairment.
cancer treatment recovery symptom tracker journal
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the oxaloacetate study find?
Among 16 evaluable breast cancer survivors, average perceived cognitive-function scores increased after eight weeks of taking oxaloacetate. Researchers also reported improvements in fatigue and physical functioning. Because there was no control group, the findings do not prove the supplement caused these changes.
How was oxaloacetate taken in the study?
Participants took 500 milligrams twice daily for eight weeks. The study enrolled 18 people, and 16 completed it.
Does the study show that oxaloacetate treats brain fog?
No. It was a small, uncontrolled study, so it can show an association between taking the supplement and reported improvement but cannot establish that oxaloacetate caused the change. A placebo-controlled trial is planned.
What side effects were reported?
The report lists gastrointestinal symptoms, including indigestion, bloating, constipation and diarrhea. It describes the treatment as generally well tolerated aside from gastrointestinal symptoms, but does not give detailed rates or establish long-term safety.
When is the next study expected?
A phase II placebo-controlled trial is expected to begin enrolling before the end of 2026, according to the report. The study’s results and enrollment details were not provided in the source material.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
